Search results for "Left ventricular hypertrophy"

showing 2 items of 102 documents

The Relationship between the Transforming Growth Factor β1 T29C Gene Polymorphism and Left Ventricular Geometry and Function in Hypertensive Subjects

2009

The distribution of the T29C TGFβ1 gene polymorphism was analyzed in 198 hypertensives with left ventricular hypertrophy (LVH) and in 235 hypertensives without LVH. Circulating TGFβ1 levels, procollagen type III levels, microalbuminuria, and left ventricular geometry and function were evaluated in all the hypertensives with LVH subgrouped according to T29C TGFβ1 gene polymorphism. Circulating TGFβ1 was evaluated by ELISA technique, procollagen type III by a specific radioimmunoassay, microalbuminuria by radioimmunoassay, and left ventricular geometry and function by echocardiography. All groups were comparable for gender, age, and sex. Regarding T29C TGFβ1 gene polymorphism, prevalence of T…

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaArticle SubjectLeft ventricular hypertrophyExcretionGene PolymorphismInternal medicineGenotypeInternal MedicinemedicineTransforming Growth Factor β1 T29C; Gene Polymorphism; Left Ventricular Geometry; Hypertensioncardiovascular diseasesTransforming Growth Factor β1 T29CEjection fractionbusiness.industryLeft Ventricular GeometryRadioimmunoassaymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologylcsh:RC666-701HypertensionMicroalbuminuriaGene polymorphismbusinessResearch ArticleTransforming growth factorInternational Journal of Hypertension
researchProduct

Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression?

2005

PURPOSE OF REVIEW The success of an antihypertensive treatment is difficult to estimate by the extent of blood pressure reduction alone. Above and beyond blood pressure values in an individual patient, it is necessary to monitor the impact of antihypertensive treatment on the development or regression of hypertension-induced early end-organ damage. The intermediate objectives or surrogate endpoints may provide additional valuable information about the level of success of a given therapy in a particular patient. Moreover, monitoring intermediate objectives may provide scientific evidence for delineating the best antihypertensive treatment. RECENT FINDINGS The importance of assessing left ven…

medicine.medical_specialtymedicine.medical_treatmentBlood PressureLeft ventricular hypertrophyEssential hypertensionInternal medicineDiabetes mellitusDiabetes MellitusInternal MedicinemedicineAlbuminuriaHumansAntihypertensive AgentsReduction (orthopedic surgery)business.industrySurrogate endpointmedicine.diseaseCarotid ArteriesBlood pressureNephrologyHypertensionCardiologyAortic pressureHypertrophy Left VentricularMicroalbuminuriabusinessCurrent Opinion in Nephrology & Hypertension
researchProduct